Table 1a.
Demographic characteristics of patients*
| Characteristic | All patients n=92 | Growth Factors n=47 | Dose Reduction n=45 | Anemic n=43 | Non-Anemic n=49 | Neutropenic n=25 | Non-neutropenic n=67 |
|---|---|---|---|---|---|---|---|
| Gender, n (%) | |||||||
| Male | 71 (77) | 37 (79) | 34 (76) | 35 (81) | 36 (73) | 17 (68) | 54 (81) |
| Female | 21 (23) | 10 (21) | 11 (24) | 8 (19) | 13 (27) | 8 (32) | 13 (19) |
| P = .81 | P = .46 | P = .26 | |||||
|
| |||||||
| Race, n (%) | |||||||
| Caucasian | 28 (30) | 13 (28) | 15 (33) | 14 (28) | 16 (33) | 8 (32) | 20 (30) |
| African-American | 39 (42) | 21 (45) | 18 (40) | 20 (47) | 19 (39) | 10 (40) | 29 (43) |
| Hispanic | 20 (22) | 9 (19) | 11 (24) | 9 (21) | 11 (22) | 6 (24) | 14 (21) |
| Other | 5 (5) | 4 (9) | 1 (2) | 2 (5) | 3 (6) | 1 (4) | 4 (6) |
| P = .85 | P = .92 | P =.96 | |||||
|
| |||||||
| Median age, years (IQR) | 47.0 (43.5, 52) | 47 (44, 52) | 47 (43, 51) | 48 (45, 52) | 45 (42, 51) | 48 (45, 53) | 46 (42, 52) |
| P = .79 | P = .13 | P = .37 | |||||
|
| |||||||
| Median body mass index cm/kg2 (IQR)† | 25.2 (23.2,28.1) | 25.7 (23.2,28.9) | 25.1 (23.2,27.8) | 24.9 (22.8, 27.6) | 26 (23.4, 29.9) | 26.5 (24.8,29.4) | 24.9 (22.8, 27.6) |
| P = .88 | P = .16 | P = .11 | |||||
|
| |||||||
| HCV genotype 1, n (%) | 77 (84) | 38 (81) | 39 (87) | 34 (79) | 43 (88) | 23 (92) | 54 (81) |
| P = .58 | P = .28 | P = .34 | |||||
|
| |||||||
| HCV-RNA level (IU/ml), n (%) | |||||||
| >1 million | 46 (50) | 22 (47) | 24 (53) | 18 (42) | 28 (57) | 14 (56) | 32 (48) |
| 100,000–1 million | 35 (38) | 18 (38) | 17 (38) | 20 (47) | 15 (31) | 10 (40) | 25 (37) |
| 10,000–100,000 | 5 (5) | 4 (9) | 1 (2) | 1 (2) | 4 (8) | 1 (4) | 4 (6) |
| <10,000 | 2 (2) | 1 (2) | 1 (2) | 2 (5) | 0 (0) | 0 (0) | 2 (3) |
| >7500 (BDNA) | 4 (4) | 2 (4) | 2 (4) | 2 (5) | 2 (4) | 0 (0) | 4 (6) |
| P = .80 | P = .18 | P = .84 | |||||
|
| |||||||
| Median necroinflammatory grade‡ | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
|
| |||||||
| Median fibrosis score§ | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
|
| |||||||
| Cirrhosis (stage 4), n (%)§ | 15/86 (17) | 6/45 (13) | 9/41 (22) | 7/39 (18) | 8/47 (17) | 6/23 (26) | 9/63 (14) |
| P = .40 | P = 1.0 | P = .21 | |||||
|
| |||||||
| Median CD4 cell count (No./mm3) | 466 (275, 595) | 479.5 (271,595) | 452 (289.5,592) | 490 (328, 605) | 449 (273, 595) | 367 (252, 509.5) | 487 (308, 641) |
| P = .88 | P = .63 | P = .059 | |||||
|
| |||||||
| HIV-1 RNA level (<400 copies/ml), n (%) | 65 (71) | 31 (67) | 34 (76) | 38 (88) | 27 (56) | 21 (84) | 44 (67) |
| P = .49 | P < .001 | P = .12 | |||||
|
| |||||||
| Patients receiving antiretroviral therapy, n (%) | 79 (86) | 39 (83) | 40 (91) | 39 (93) | 40 (82) | 22 (92) | 57 (85) |
| P = .36 | P = .13 | P = .51 | |||||
*
Some patients were counted twice; patients with anemia and neutropenia are included in the total for anemic and neutropenic patients. Data available on all patients unless indicated below.
†
Body mass index unavailable for 2 patients.
‡
Scores range from 0 to 4, with higher scores indicating more activity.20 Grade unavailable for 6 patients.
§
Scores range from 0 to 4, with higher scores indicating more extensive fibrosis.20 Stage unavailable for 6 patients.
¶
CD4 count unavailable for 2 patients.